Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Newborn screening for severe combined immune deficiency (technical and political aspects)

Newborn screening for severe combined immune deficiency (technical and political aspects) Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Newborn screening for severe combined immune PINION deficiency (technical and political aspects) Lisa Kobrynski Purpose of review Newborn screening for severe combined immune deficiency (SCID) has been implemented in more than half of the states in the United States. Despite the success of these programs, numerous challenges remain for implementing newborn screening. The present review will focus on technical, programmatic, and political aspects pertinent to newborn screening for SCID. Recent findings Recent data from newborn screening in 11 U.S. programs suggest that the birth prevalence of SCID is higher than previous estimates. In addition, a large number of other conditions causing T-cell lymphopenia have been detected. Several European countries have initiated pilot screening for SCID. Significant cost savings for treatment of infants with SCID detected at birth, compared with later in life, has been demonstrated. Published evidence of the favorable cost–benefit ratio for screening supports implementation of universal SCID newborn screening. Summary SCID fulfills criteria for a condition that should be included in routine newborn screening. Data presented from multiple newborn screening programs in the United States and Europe have shown that high throughput screening of all newborns is cost-effective. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in Allergy & Clinical Immunology Wolters Kluwer Health

Newborn screening for severe combined immune deficiency (technical and political aspects)

Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/newborn-screening-for-severe-combined-immune-deficiency-technical-and-rUI7v9JiZC

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1528-4050
eISSN
1473-6322
DOI
10.1097/ACI.0000000000000221
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-allergy by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Newborn screening for severe combined immune PINION deficiency (technical and political aspects) Lisa Kobrynski Purpose of review Newborn screening for severe combined immune deficiency (SCID) has been implemented in more than half of the states in the United States. Despite the success of these programs, numerous challenges remain for implementing newborn screening. The present review will focus on technical, programmatic, and political aspects pertinent to newborn screening for SCID. Recent findings Recent data from newborn screening in 11 U.S. programs suggest that the birth prevalence of SCID is higher than previous estimates. In addition, a large number of other conditions causing T-cell lymphopenia have been detected. Several European countries have initiated pilot screening for SCID. Significant cost savings for treatment of infants with SCID detected at birth, compared with later in life, has been demonstrated. Published evidence of the favorable cost–benefit ratio for screening supports implementation of universal SCID newborn screening. Summary SCID fulfills criteria for a condition that should be included in routine newborn screening. Data presented from multiple newborn screening programs in the United States and Europe have shown that high throughput screening of all newborns is cost-effective.

Journal

Current Opinion in Allergy & Clinical Immunology – Wolters Kluwer Health

Published: Dec 1, 2015

There are no references for this article.